Belgium· BE-AMP-SAM599920-00
Amifampridine Serb 10 mg
A amifampridine product containing amifampridine phosphate, registered in Belgium by SERB. The same ATC class is registered in 16 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Amifampridine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Amifampridine · ATC N07XX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amifampridine costs, country by country.
Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amifampridine · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- FR France$3657.38
- CH Switzerland$75.59
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Amifampridine Phosphate
- Manufacturer
- SERB
- Country
- Belgium (BE)
- ATC code
- N07XX05
- ATC class
- Amifampridine
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for amifampridine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amifampridine · interactions on record
82 records
- 4 severe
- 78 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Amifampridine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United Kingdom3,4-Diaminopyridine 10mg tabletsSpecial Order
- NetherlandsAmifampridine Accord 10 mg tablettenAccord Healthcare B.V.
- GermanyAmifampridin AccordAccord Healthcare B.V.
- NorwayAmifampridine AccordAccord Healthcare B.V.
- CzechiaAMIFAMPRIDINE SERBSERB S.A., Brusel
- FranceAMIFAMPRIDINE SERB 10 mg, compriméSERB (BELGIQUE)
- PolandAmifampridine Medical ValleyMedical Valley Invest AB
- FinlandAmifampridine SERBSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Germany · Amifampridin Accord, Amifampridin Amarox
- France · Amifampridine Amarox, Amifampridine Biogaran
- Hungary · Amifampridine Accord
- Iceland · Amifampridine Serb, Firdapse
- Italy · Amifampridina Accord
- Liechtenstein · Amifampridine Serb, Firdapse
- Netherlands · Amifampridine Accord, Amifampridine Amarox
- Norway · Amifampridin Medical Valley, Amifampridine Accord
- Poland · Amifampridine Medical Valley
- Portugal · Amifampridina Accord, Amifampridina Generis
- Slovenia · Amifampridin Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f613e314-337e-4399-bfb7-63de08d098ac GET /v1/drugs/f613e314-337e-4399-bfb7-63de08d098ac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Amifampridine Serb 10 mg",
"name_fr": "Amifampridine Serb 10 mg",
"name_nl": "Amifampridine Serb 10 mg",
"amp_code": "SAM599920-00",
"strengths": [
"10.0000"
],
"pack_count": 3,
"substances": [
"Amifampridine Phosphate",
"Amifampridine"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Amifampridine",
"authorisation_numbers": [
"EU/1/22/1646/003",
"EU/1/22/1646/001",
"EU/1/22/1646/002"
]
}See everything about amifampridine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.